Industries > Pharma > Global Liquid Biopsy Market Forecast to 2029

Global Liquid Biopsy Market Forecast to 2029

Instruments, Kits and Reagents, Services, Blood Sample, Urine Sample, Circulating Tumour Cell (CTC), Circulating Tumour DNA (ctDNA), Exosomes, Breast Cancer, Colorectal Cancer, Liver Cancer, Lung Cancer, Prostate Cancer, Hospitals, Diagnostic Laboratories, Academic Institutions and Cancer Research Centres

PUBLISHED: 29 November 2019
PAGES: 180
PRODUCT CODE: PHA0620
SUBMARKET: Diagnostics

Clear
WOOCS 2.2.1
SKU: PHA0620 Categories: , Tags: ,

The global liquid biopsy market is estimated to reach $1,173.5m in 2019. The kits & reagents submarket holds the biggest share of the global liquid biopsy market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 180-page report you will receive 179 charts– all unavailable elsewhere.

The 180-page report provides clear detailed insight into the liquid biopsy market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Liquid Biopsy Market forecast to 2029

• Revenue forecasts for the Liquid Biopsy Market Forecast by Product to 2029:
• Instruments
• Kits & Reagents
• Services

Each submarket is further segmented by regional market.

• Revenue forecasts for the Liquid Biopsy Market Forecast by Sample to 2029:
• Blood
• Urine
• Other Samples

Each submarket is further segmented by regional market.

• Revenue forecasts for the Liquid Biopsy Market Forecast by Biomarker to 2029:
• Circulating Tumor Cells (CTC)
• Circulating Tumor DNA (CtDNA)
• Exosomes
• Other Biomarkers

Each submarket is further segmented by regional market.

• Revenue forecasts for the Liquid Biopsy Market Forecast by Cancer to 2029:
• Breast Cancer
• Colorectal Cancer
• Liver Cancer
• Lung Cancer
• Prostate Cancer
• Other Cancers

Each submarket is further segmented by regional market.

• Revenue forecasts for the Liquid Biopsy Market Forecast by End-User to 2029:
• Hospitals
• Diagnostic Laboratories
• Academic Institutions
• Cancer Research Centres

Global Liquid Biopsy Market Forecast to 2029

Each submarket is further segmented by regional market.

• Revenue forecasts for the Liquid Biopsy Market Forecast by Region to 2029:

North America:
• U.S.
• Canada
• Mexico

Europe:
• Germany
• UK
• France
• Italy
• Spain
• Russia
• Rest of Europe

Asia-Pacific:
• Japan
• China
• India
• Australia
• South Korea
• Rest of Asia-Pacific

LAMEA:
• Brazil
• Turkey
• Venezuela
• Saudi Arabia
• Republic of South Africa
• Rest of LAMEA

• Profiles of the selected leading companies:
• Abbott
• Beckman Coulter
• Biocept, Inc.
• Bio-Rad Laboratories
• Biotime
• Caris Lifesciences
• F. Hoffman-La Roche
• Guardant Health, Inc.
• Illumina, Inc.
• MDxHealth SA
• Menarini Silicon Biosystems, Inc.
• Myriad Genetics, Inc.
• OPKO Health, Inc.
• Qiagen N.V.
• Sysmex Inostics
• Trovagene, Inc.

• This report discusses Drivers, Restraints, Opportunities and Threats of the global liquid biopsy market

• The report also includes a PESTLE Analysis of the Global Liquid Biopsy Market

• Key questions answered by this report:
• How is the Liquid Biopsy market evolving?
• What are the drivers and restraints for the growth of the liquid biopsy market?
• What are the market shares of each segment of the overall liquid biopsy market in 2018?
• How will each liquid biopsy submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2029?
• How will the market shares for each liquid biopsy submarket develop to 2029?
• Which individual therapies will prevail and how will these shifts be responded to?
• What will be the main driver for the overall market to 2029?
• How will political and regulatory factors influence the regional markets and submarkets?
• How will the market shares of the national markets change by 2029 and which geographical region will lead the market by 2029?
• Who are the leading players and what are their prospects over the forecast period?
• How will the industry evolve during the period between 2019 and 2029?

Visiongain’s study is intended for anyone requiring commercial analyses for the Global Liquid Biopsy Market. You find data, trends and predictions.

Buy our report today Global Liquid Biopsy Market Forecast to 2029: Instruments, Kits and Reagents, Services, Blood Sample, Urine Sample, Circulating Tumour Cell (CTC), Circulating Tumour DNA (ctDNA), Exosomes, Breast Cancer, Colorectal Cancer, Liver Cancer, Lung Cancer, Prostate Cancer, Hospitals, Diagnostic Laboratories, Academic Institutions and Cancer Research Centres.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Global Liquid Biopsy Market Forecast to 2029


Download sample pages

Complete the form below to download your free sample pages for Global Liquid Biopsy Market Forecast to 2029


Latest Pharma news

Visiongain Publishes Generic Drugs Market Report 2020-2030

The 431-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.

03 July 2020

READ

Visiongain publishes Clinical Workflow Solutions Market Report 2020-2030

Where is the Clinical Workflow Solutions market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.

03 July 2020

READ

Visiongain Publishes Clinical Trials Market Report 2020-2030

With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.

01 July 2020

READ

Visiongain Publishes Clinical Risk Grouping Solutions Market Report 2020-2030

The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.

01 July 2020

READ